The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol.

This comprehensive study quantifies world markets 2000 to 2010 in the following therapeutic categories: examined at the level of manufacturers’ revenues in each of the following product categories:

• allergy and respiratory drugs,
• analgesics (including NSAIDs) and anti-rheumatic drugs,
• anesthesia,
• anti-infectives,
• cancer drugs,
• cardiovascular drugs,
• CNS drugs,
• gastrointestinal drugs,
• hormone drugs, and
• ophthalmic drugs.

In addition to market size and growth, market share of leading competitors, the report discusses regulatory, clinical, and business trends and issues in detail, including

• how the Hatch-Waxman Act works and fails to work,
• how FDA funding plans will affect filings and approvals in the coming years,
• what strategies big pharma is using to fend off market share erosion, like autorized generics and aggressive patent filing,
• how generic biologics fit in the picture,
• how M&A activity is changing the landscape, and
• many more

The report also details the big-name drugs set to lose protection over the next 6 years and what level of revenue is at stake for whom.

The report also includes profiles of the top players, including:

• Actavis Group
• Altana Pharma AG
• Andrx Corporation
• Apotex Group
• Aurobindo Pharma, Ltd.
• Barr Laboratories, Inc.
• Bedford Laboratories
• Lannett Company, Inc.
• Mylan Laboratories, Inc.
• Orchid Chemicals and Pharmaceuticals, Ltd.
• Par Pharmaceuticals, Inc.
• Perrigo Company
• PLIVA Pharmaceuticals, Inc.
• Ranbaxy Laboratories, Ltd.
• Roxane Laboratories, Inc.
• Sandoz International, GmbH
• Taro Pharmaceutical Industries Ltd.
• TEVA Pharmaceutical Industries, Ltd.
• Watson Pharmaceuticals, Inc.
• United Research Laboratories and Mutual Pharmaceutical Company
• Zydus Pharmaceuticals, Inc.

Related Reports:

The World Market for Gastrointestinal Endoscopy Equipment
Jan 1, 2009 - KLI1646595 - $3,500.00

The World Market for Molecular Diagnostics
Jan 1, 2009 - KLI1914575 - $3,995.00

Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products
Nov 1, 2008 - KLI1816262 - $3,995.00

Smoking Cessation: World Markets
Nov 1, 2008 - KLI1646594 - $3,500.00

Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends in Egypt, Jordan, Israel, Saudi Arabia and UAE)
Nov 1, 2008 - KLI1646593 - $3,300.00

Glucose Testing Markets
Nov 1, 2008 - KLI1911068 - $1,995.00

Kalorama Medical Device Market Research Bundle: Infusion Pumps, Minimally Invasive Devices, Syringes, Hip and Knee Implants, Respiratory Equipment, Asian Device Markets, OEM Contract Manufacturing, Reusable Equipment, Catheters)
Oct 1, 2008 - KLI1927457 - $9,995.00

HIV: Markets for Diagnostics and Therapeutics
Oct 1, 2008 - KLI1646600 - $3,500.00

Worldwide In Vitro Diagnostics ( IVD ) Market Research Bundle (Worldwide Market for In Vitro Diagnostic Tests, SNP Genotyping Markets, Companion Diagnostics, Testing Services Markets)
Oct 1, 2008 - KLI1927625 - $7,995.00

Minimally Invasive Surgical Devices, World Market
Sep 1, 2008 - KLI1614100 - $3,500.00